EpiCast Report：非アルコール性脂肪性肝炎 (NASH) の疫学予測
EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025
|出版日||ページ情報||英文 56 Pages
|EpiCast Report：非アルコール性脂肪性肝炎 (NASH) の疫学予測 EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025|
|出版日: 2016年12月01日||ページ情報: 英文 56 Pages||
世界の主要7ヶ国 (米国、フランス、ドイツ、イタリア、スペイン、英国、日本) における非アルコール性脂肪性肝炎 (NASH) の総患者数は、2015年の60,325,647人から、2025年には64,273,379人まで増加する (年間平均増加率0.65％) と予測されています。
当レポートでは、世界の主要7ヶ国における非アルコール性脂肪性肝炎 (NASH) について調査分析し、疾患の背景、危険因子と併存疾患、世界の動向、疫学予測などについて、体系的な情報を提供しています。
Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of steatosis (fatty liver), in addition to liver inflammation and damage (NIDDK, 2014). Unlike alcoholic liver disease, NASH occurs in those who drink little or no alcohol. NASH usually presents with few or no symptoms, and most people affected with the disease feel healthy and are unaware they have a problem (NIDDK, 2014). However, symptoms including fatigue, weight loss, and weakness emerge once the disease has progressed to a more advanced stage, like cirrhosis. NASH is suspected if elevated liver enzymes are detected during routine blood panels, but it is only definitively diagnosed when a liver biopsy is performed (NIDDK, 2014).
Both NASH and non-alcoholic fatty liver (NAFL) are histologically categorized under the umbrella of non-alcoholic fatty liver disease (NAFLD). NAFL is defined as the presence of a fatty liver with no evidence of hepatocellular injury or fibrosis, whereas NASH is defined as the presence of fatty liver and inflammation with evidence of hepatocyte injury (in the form of ballooning), with or without fibrosis.
Epidemiologists forecast that the total prevalent cases of NASH in the 7MM will grow by 0.65% per year over the next 10 years, from 60,325,647 cases in 2015, to 64,273,379 cases in 2025. In the 7MM, the US will have the highest number of total prevalent cases throughout the forecast period, accounting for 56.85% of all total prevalent cases in the 7MM in 2015. When analyzing the individual markets, more than 85.00% of the total prevalent cases of NASH occurred in ages 20 years and older and more cases occurred in men compared with women.
7MM will see an increase in the diagnosed prevalent cases of NASH from 16,952,459 cases in 2015 to 31,000,983 cases in 2025, at the rate of 8.29%. Diagnosed prevalent cases are forecast to increase faster than total prevalent cases due to expected increase in diagnosis rate, as indicated by primary research. Among the diagnosed prevalent cases of NASH, obesity is the most common comorbidity, where 78.68% of the NASH cases also are obese.
The report “EpiCast Report: Non-Alcoholic Steatohepatitis - Epidemiology Forecast to 2025” provide an overview of the risk factors and global trends of NASH in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases (both diagnosed and undiagnosed) of NASH segmented by age and sex. It also includes a 10-year epidemiological forecast for the diagnosed prevalent cases of NASH, which are further segmented by comorbid disorders, including obesity, diabetes mellitus type 2 (T2D), hyperlipidemia, and hypertension in these markets.